THE health service has been accused of squandering hundreds of millions of euro over the past decade by paying massively inflated prices for prescription drugs.
New industry figures seen by the Irish Independent reveal how manufacturers are being paid up to 18 times more for some generic drugs in Ireland than for the same products in the UK.
The figures indicate that up to €98m a year of taxpayers' money could be saved on the medical card scheme alone if UK generic prices for some of the most popular medicines were being paid here.
The inflated costs -- which stem from agreements between the HSE and the pharmaceutical industry -- have been blamed on a number of factors.
These include the relatively small size of the Irish market and fears that drug companies could stop supplying certain vital products if forced to accept lower prices.
Industry figures show that the top 20 medicines prescribed under the medical card scheme cost the State almost €360m each year.
Nine of these brands have generic versions which are widely sold at a fraction of the original brand's cost in the UK -- despite being of equal quality.
However, in Ireland the same generics are only slightly cheaper than the branded versions.
Were these prices slashed to UK levels, between €89m and €98m could be saved on the medical card scheme each year, according to estimates.